Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular ...

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...

Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy ...

Sarepta Therapeutics Inc. shares plunged after European regulators rejected its gene therapy Elevidys, intensifying scrutiny on the drugmaker after it was pressured to halt shipments of its treatment ...

Friday said that the European Medicines Agency has issued a negative opinion on the conditional marketing authorization for Elevidys, intended for ambulatory patients aged three to seven with Duchenne ...

Detailed price information for Doordash Inc Cl A (DASH-Q) from The Globe and Mail including charting and trades.

The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Trimble is now the #23 analyst pick, moving up by 1 spot. This rank is ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previously approved by the Compensation ...

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT ...

Investing.com - JPMorgan has reduced its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $28.00 from $30.00 while maintaining an Overweight rating on the stock.